[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![andrewcaravello Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::244291506.png) Andrew Caravello, DO [@andrewcaravello](/creator/twitter/andrewcaravello) on x 1090 followers
Created: 2025-07-10 17:49:52 UTC

🔬 The Silence Was the Strategy, and the Signal Was in the Cells

TL;DR 🪶 This isn’t a thread. It’s a blueprint.
$NWBO didn’t stay silent by accident. It built and protected the first scalable platform to train dendritic cells against tumor vasculature,  and proved it in the largest glioblastoma trial ever run. Mayo Clinic helped validate the mechanism. Ivy quietly backed the science.
But NWBO developed it, licensed it, and owns it.

🕰️ Estimated reading time: ~8–10 min

Northwest Biotherapeutics has long been defined by what it didn’t say. While most biotech companies rushed to publish splashy press releases and issue bold projections, NWBO kept building quietly. For years, the company absorbed criticism for its silence, its absence from conferences, its failure to trumpet success. But beneath that stillness was a structural buildout more intricate than nearly anyone understood.

That silence allowed something rare to happen: NWBO was able to architect an immunotherapy framework that now appears to connect directly to one of the most quietly validated immune platforms in glioblastoma research, the Mayo Clinic dendritic cell vaccine program.

This isn’t theory. It’s visible in documents. In filings. In funding trails. In shared antigens. And now, finally, in peer-reviewed journals, and direct disclosures from the Ivy Foundation.

At the core of the Mayo platform, funded by the Ivy Foundation and developed under the leadership of Dr. Allan Dietz and Dr. Ian Parney, is a two-part immunotherapy strategy:

1.Take a patient’s own dendritic cells, the cells that teach T cells what to attack.
2.Pulse them not with that patient’s own tumor, but with a pooled, well-characterized lysate library derived from other patients’ glioblastoma cell cultures.

The result is a vaccine that is both personalized and standardized. It’s customized to the patient’s immune system, but loaded with shared tumor antigens, including, crucially, tumor blood vessel antigens.

What makes this so relevant to NWBO is not just the similarity in approach. It’s that this Mayo platform was built using a GMP-validated lysate library licensed to Mill Creek Life Sciences. Mayo holds equity. The inventors receive royalties. And the same scientific team that created this platform is named on filings, patents, and published studies that align, precisely, with the method NWBO has quietly evolved toward in its Specials program and post-Phase X development.

And now the proof is public. The Ivy Foundation’s own project listing spells it out: the goal was to create a scalable, monitorable, potent vaccine using autologous dendritic cells and pooled lysate from multiple patients’ tumor cultures. The project was expanded to include recurrent glioblastoma, ran from 2013 to 2021, and was backed by Mayo’s Human Cell Therapy Lab under Dr. Dietz.

The clinical data is published. Safety was excellent. Manufacturing was consistent. Antigen-specific T-cell responses were observed. Long-term survivors emerged.

This wasn’t an experiment. It was a blueprint.

And it mirrors exactly what NWBO’s platform has become, a fully personalized dendritic cell vaccine, loaded not with variable tumor lysate from a single patient, but with curated antigen libraries designed to include consistent, vascular targets like HER2, VEGFR, and FAP.

These are not just tumor markers. These are infrastructure targets. These are the scaffolds of immune exclusion. And they are the protected territory of the Roswell Park patent portfolio, the very one NWBO now controls.

When you align all of this, the Ivy-funded Mayo trials, the patent filings, the antigen overlap, the immune monitoring protocols, the GMP manufacturing systems, the appearance of Flaskworks, and the legal protections around vascular targeting, a picture begins to emerge.

NWBO is not a company waiting to commercialize a single product. It is a company that secured the immune playbook while everyone else was looking for noise.

And Mayo Clinic, quietly, professionally, institutionally, appears to be part of that immune architecture.

The silence wasn’t absence. It was orchestration.

🧠 The Real Target Was Never Just the Tumor (It Was the Blood Vessels)

In cancer, the focus has always been on destroying the tumor. But the most effective immune strategies don’t stop there. They dismantle the infrastructure the tumor relies on. The real vulnerability isn’t the tumor mass itself. It’s the vasculature that feeds it.

Tumors create their own blood supply. This network is not normal, it is leaky, swollen, erratic, and selectively immune-excluding. These vessels form the metabolic lifeline of the tumor and simultaneously wall off the immune system. And the endothelial cells lining these vessels express abnormal surface markers not found on healthy adult blood vessels. These are known as tumor blood vessel antigens, or TBVAs.

TBVAs are not random mutations. They are what scientists call stochastic expressions, that is, they appear in a probabilistic and disorderly fashion, but they are consistently found across many tumors and patients. Examples include HER2, VEGFR, and FAP, structural and signaling proteins that are present on tumor vasculature but largely absent from healthy adult vessels.

And that makes them highly immunogenic.

By pulsing dendritic cells with TBVAs outside the body, under optimized lab conditions, scientists can turn those cells into immune instructors. When these dendritic cells are reintroduced into the body, they train T cells to seek and destroy the tumor’s blood vessels. CD8+ T cells cut off the tumor’s supply lines. CD4+ T cells reshape the immune environment. The entire tumor microenvironment becomes vulnerable. Checkpoint inhibitors begin to function. Cytokines can enter. The tumor loses its shelter.

This isn’t just a therapy. It’s a systemic dismantling of the tumor’s defenses, and it’s the foundation of the Roswell Park patent estate, now exclusively licensed by Northwest Biotherapeutics.

These patents don’t just describe dendritic cell vaccines in general. They specifically protect the use of dendritic cells to generate vascular-targeted immune responses, especially against HER2, VEGFR, and FAP, in solid tumors. This includes the method of pulsing DCs with those antigens, reintroducing them to the body, and enabling downstream immune effects.

Which brings us back to Mayo Clinic.

The lysate libraries developed and used at Mayo, with full Ivy Foundation funding and authored by Dr. Ian Parney and Dr. Allan Dietz, were created using glioblastoma tumor cultures from multiple patients. These libraries were standardized, immune-characterized, and documented to express HER2, VEGFR, and FAP.

Mayo then pulsed autologous dendritic cells with this pooled lysate under cGMP conditions, reintroduced them into patients, and observed vascular-antigen-specific immune responses, particularly CD8+ T cell activation against gp100 and other shared antigens. The data, published in Neuro-Oncology Advances, show long-term survivors, a XXX% manufacturing success rate, and full immune monitoring over multiple years.

This is not incidental. This is a real-world execution of the exact immune logic covered by NWBO’s Roswell patents.

So what does that mean about the relationship between NWBO and Mayo Clinic?

Mayo built and published a successful immune protocol using autologous DCs and vascular antigen-rich lysate. NWBO now controls the intellectual property that governs the use of that method in solid tumors. That means Mayo’s work exists (knowingly or not) inside NWBO’s IP framework.

If Mayo intends to commercialize, expand, or license its platform, it will do so within the legal and immune architecture that NWBO now owns. And if NWBO chooses to leverage Mayo’s lysate libraries, manufacturing know-how, or published immunological insights, it will be doing so from a position of patent control.

Whether or not the partnership is public, the alignment is real. Mayo helped validate the immune logic. NWBO holds the keys to its commercial deployment.

That is not coincidence. That is convergence.

NWBO doesn’t just resemble Mayo’s program. It owns the protected mechanism that makes it function.

And that mechanism, vascular-targeted dendritic cell therapy using pooled antigen sources, is no longer just science.

It’s architecture.

It’s patented.

And it’s live.

🧩 From Blueprint to Execution (The System Is Already in Place)

What NWBO has done over the past decade is not simply build a product. It has constructed an immunological operating system, one that is automated, regulated, and geographically deployable.

That’s where Flaskworks enters the story.

NWBO didn’t buy just any automated cell processing device. It acquired a platform that was purpose-built to solve the core manufacturing bottleneck in dendritic cell therapy: how to grow, mature, and harvest delicate adherent immune cells without compromising their surface markers or potency.

What makes Eden XXX so pivotal isn’t just that it automates dendritic cell manufacturing. It’s that it was rebuilt (post-acquisition) to meet full GMP compliance, with closed-loop processing, temperature-controlled harvesting, and electronic batch logging. Unlike traditional CAR-T systems that focus on suspension cells and expansion, Eden XXX was engineered specifically for adherent immune cells like dendritic cells. It can grow, pulse, and gently release DCs without enzymes, using a proprietary Peltier-based cooling method. This isn’t a lab prototype. It’s a production system, designed to drop into hospital cleanrooms under SI XX and generate patient-specific vaccines on demand, with traceability, sterility, and scale.

The Flaskworks Eden XXX system:

•Grows DCs in a closed, sterile, programmable chamber
•Pulses them with lysate at precisely timed intervals
•Harvests them without enzymes or mechanical scraping, using a patented Peltier cooling method that gently detaches the cells without damaging them

It does all this while tracking every variable, pH, temperature, optical density, and logging the data in uneditable GMP-compliant records.

This is not theoretical. It is installed, validated, and operational. And it is what allows DCVax-L to scale from bespoke batches to a distributable therapeutic model.

But even Flaskworks wouldn’t matter without a regulatory framework to match it.

That’s where the UK’s Statutory Instrument 2025 No. XX comes in, the legal backbone of NWBO’s deployment strategy.

SI XX codified, for the first time in the world, a hub-and-spoke manufacturing architecture for advanced therapies. Under this structure:

•A central GMP facility (the hub) holds the license and quality control authority
•Regional hospitals (spokes) perform final preparation steps, like thawing and administering the patient-specific vaccine, without having to hold full manufacturing licenses
•The system is governed under a single quality file, with the hub responsible for all validation, release, and oversight

This structure allowed NWBO to activate its UK Specials program under full legal compliance, delivering DCVax-L to patients across the country, with Flaskworks units operating inside hospital cleanrooms, managed under central command.

It’s not just compliant. It’s strategically designed for scale, equity, and speed.

And then came the patents.

For years, the Roswell method, using dendritic cells to target tumor blood vessels, was a quiet cornerstone. NWBO had secured the license. The filings were active. The claims were specific. But the company said nothing.

Until Linda Powers made the decision to put it in writing, publicly.

That wasn’t just a formality. It was a signal. A signal that the timing was right, that the legal structure was complete, and that the mechanism was now safely protected.

You don’t name your IP until you’ve locked it down.
If she had spoken too soon, the method would have been exposed and unprotectable.
You don’t bring the Roswell patents into the open unless you’ve satisfied the terms, cleared the milestones, and built the platform that can hold them.

And Linda Powers did just that.

She waited until Flaskworks was validated. Until SI XX was active. Until DCVax-L was being delivered under Specials access. Until the pooled lysate model, immunologically identical to what Mayo built, was fully integrated.

Then she brought the patents forward.

That public act alone should speak volumes. You don’t surface patents unless you’re ready to defend them. Unless you intend to enforce them. Unless you’ve done the work to deserve them.

And here’s why that matters.

At its core, a biotech company is not just a product. It’s a protected method. A process you own that others cannot legally copy.

Because if anyone else can take what you’ve built and do it themselves, it’s not worth investing in. It’s not a company. It’s just an idea, and ideas without protection don’t survive in this field.

What NWBO has built, with the Roswell patents, Flaskworks, pooled antigen libraries, and global regulatory positioning, is something you cannot simply recreate. The method is patented. The equipment is patented. The regulatory structure is in place. And the entire system is now layered with legal protections that stretch across manufacturing, immune activation, and clinical use.

That’s why this isn’t just a trial. It’s a platform. A company is defined by what it owns that others can’t take.

And NWBO owns the immune engine in writing, in law, and now in action.

In an industry crowded with speculation and premature hype, she built something rare, a biotech platform grounded in science, wrapped in law, scaled through automation, and sequenced with intention.

The silence was never hesitation.

It was orchestration.

It was the blueprint, and now it’s operational.

In Linda we trust. 🗽

🧠 The Real Target Was Never Just the Tumor (It Was the Blood Vessels)

In cancer, the focus has always been on destroying the tumor. But the most effective immune strategies don’t stop there. They dismantle the infrastructure the tumor relies on. The real vulnerability isn’t the tumor mass itself. It’s the vasculature that feeds it.

Tumors create their own blood supply. This vascular system is not normal, it’s swollen, erratic, and often impenetrable to immune cells. It starves the immune system while nourishing the tumor. Most importantly, these vessels express abnormal surface proteins, antigens that are largely absent from normal blood vessels. These are called tumor blood vessel antigens (TBVAs).

TBVAs include targets like HER2, VEGFR, and FAP. These proteins aren’t random mutations. They are what scientists call stochastic expressions, appearing unpredictably at the individual tumor level but consistently across patients and cancer types. Because they’re shared, stable, and exposed on the vasculature, they make ideal immune targets.

When dendritic cells are pulsed with these TBVAs under carefully controlled lab conditions, they become immune instructors. Once reintroduced into the body, they train CD8+ T cells to attack tumor blood vessels directly, CD4+ T cells to reshape the surrounding immune landscape, and help break the tumor’s physical and metabolic defenses. Checkpoint inhibitors begin to work. Cytokines can enter. The tumor loses its sanctuary.

This is not just stimulation. It’s strategic dismantling. It’s vascular sabotage.

And it is legally protected.

🔐 What the Roswell Patents Cover (And Why NWBO Controls the Space)

The Roswell Park patents, now exclusively licensed to Northwest Biotherapeutics, do not describe general dendritic cell vaccines. They specifically cover:

•The use of dendritic cells to generate immune responses against tumor blood vessel antigens (TBVAs)
•Including targets like HER2, VEGFR, and FAP
•In the context of solid tumors
•Using an ex vivo pulsing and reinfusion method

This is a method patent. That means even if another group uses different source material , like a pooled lysate instead of a recombinant peptide, if the downstream immune mechanism is the same, the license applies.

This matters because NWBO now owns the exclusive rights to commercialize this approach across all solid tumors. Others may test it. Others may even publish. But for anyone to bring it to market, NWBO must be involved, or they are in violation.

🏥 Mayo Clinic Validated the Method NWBO Now Legally Controls

From 2013 to 2021, Mayo Clinic conducted a trial titled:

“Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Recurrent Glioblastoma”
ID: NCT03360708

In this trial:
•Dendritic cells were autologous, harvested from each patient
•Tumor antigens came from a shared lysate library built from GBM cell lines
•That lysate was manufactured under GMP conditions and included known shared antigens like HER2, VEGFR, and FAP

Mayo pulsed the DCs with this lysate, administered them in multiple cycles, and observed:
•CD8+ T cell responses to known antigens
•Pseudoprogression, a classic sign of immune activation
•Long-term survivors, even in recurrent GBM
•Full immune profiling confirming modulation of key leukocyte populations over time

This is not a speculative pilot. It is a real-world, published execution of the Roswell method, the same one NWBO now exclusively owns.

Quietly connecting these threads is the Ben and Catherine Ivy Foundation, which has not only funded Mayo Clinic’s pooled-lysate dendritic cell trials, but also backed Swedish Neuroscience Institute’s early Phase II DCVax trial in 2011, conducted under NWBO’s IND and protocol design. The principal investigator? Dr. Charles Cobbs, who later appeared as a co-author on NWBO’s Phase X publication. Cobbs would go on to receive additional Ivy funding for a Phase X trial combining autologous dendritic cells with PD-1 inhibitors. He is one of the few scientists to have worked under both Ivy-funded institutional platforms and NWBO’s own clinical programs, stitching together the field’s developmental arc.

In effect, Ivy helped fund every major axis of dendritic cell vaccine evolution, the GBM lysate libraries at Mayo, the PD-1 combos at Swedish, and the early DCVax-Brain deployment itself. The foundation didn’t pick sides. It quietly backed the method, and now that method is protected, under NWBO’s license.

🧩 What This Means for Mayo, Mill Creek, and NWBO

Mayo developed the lysate.
Mill Creek produced it.
The trial proved it works.
But the protected legal framework now belongs to NWBO.

As the thesis puts it:

“Mayo innovates and validates new principles, Mill Creek commercializes the essential tools and reagents needed to execute those principles, and a company like NWBO can then integrate the validated concepts and tools into a commercially viable therapeutic platform.”

Whether Mayo is currently sublicensed, operating under legacy academic use, or has paused commercial plans, the outcome is the same: any deployment of this vascular-targeted DC model now falls under NWBO’s IP domain.

NWBO doesn’t have to invent what Mayo proved.
It just has to protect it.
And now it does, in writing.

🛡️ Why This Eliminates Fear

The most common fear among investors or observers is: “What if someone else does this faster? What if Mayo just runs with it? What if NWBO gets cut out?”

But here’s the reality:

•If someone can take what you’ve built and do it without you, it’s not a company.
•That’s what patents prevent. That’s what gives investors protection.
•NWBO has the license. It controls the method. And the most validated clinical version of that method (Mayo’s trial) is now structurally nested inside NWBO’s patent estate.

This is not theory. It’s not about hope.
It’s about ownership. And NWBO owns the immune engine.

No one can legally commercialize this without NWBO.
If they try, they’ll have to negotiate.
And when that day comes, NWBO won’t be asking for permission.
They’ll be setting the terms.

📜 Summary

Mayo proved the biology.
Mill Creek enabled the manufacturing.
NWBO holds the license, the patents, and the commercial path.

This platform is no longer vulnerable. It’s protected.
It’s no longer theoretical. It’s validated.
And it’s no longer just an idea. It’s architecture.

NWBO doesn’t just resemble Mayo’s approach. It owns the mechanism that made it succeed.
And that mechanism, vascular-targeted dendritic cell therapy using pooled lysate, is no longer just science.

It’s operational.

It’s protected.

It’s live. 🔒

$MRK $BMY $AZN $PFE $REGN $GILD $LLY $ROG $SNY $AMGN $NVS $ABBV $BIIB $BNTX $VRTX $DNLI $JNJ $GSK $RHHBY $MODN $ALNY $KRTX $HZNP $INCY

#DCVax #GBM #Immunotherapy #CellTherapy #CancerVaccine
#BrainTumor #DendriticCells #TumorMicroenvironment #MHRA #RoswellPark


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1943367078607753579/c:line.svg)

**Related Topics**
[ivy](/topic/ivy)
[mayo](/topic/mayo)
[$nwbo](/topic/$nwbo)

[Post Link](https://x.com/andrewcaravello/status/1943367078607753579)